Literature DB >> 1904891

Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.

A E Epstein1, J T Bigger, D G Wyse, D W Romhilt, R A Reynolds-Haertle, A P Hallstrom.   

Abstract

To test the hypothesis that suppression of ventricular arrhythmias by antiarrhythmic drugs after myocardial infarction improves survival, the Cardiac Arrhythmia Suppression Trial (CAST) was initiated. Suppression was evaluated before randomization during an open label titration period. Patients whose arrhythmias were suppressed were randomized in the main study and those whose arrhythmias were partially suppressed were randomized in a substudy. Overall survival and survival free of arrhythmic death or cardiac arrest were lower [corrected] in patients treated with encainide or flecainide than in patients treated with placebo. However, the death rate in patients randomized to placebo therapy was lower than expected. This report describes the survival experience of all patients enrolled in CAST and compares it with mortality in other studies of patients with ventricular arrhythmias after myocardial infarction. As of April 18, 1989, 2,371 patients had enrolled in CAST and entered prerandomization, open label titration: 1,913 (81%) were randomized to double-blind, placebo-controlled therapy (1,775 patients whose arrhythmias were suppressed and 138 patients whose arrhythmias were partially suppressed during open label titration); and 458 patients (19%) were not randomized because they were still in titration, had died during titration or had withdrawn. Including all patients who enrolled in CAST, the actuarial (Kaplan-Meier) estimate of 1-year mortality was 10.3%. To estimate the "natural" mortality rate of patients enrolled in CAST, an analysis was done that adjusted for deaths that might be attributable to encainide or flecainide treatment either during prerandomization, open label drug titration or after randomization. Because the censoring procedure excluded patients treated with encainide or flecainide after randomization, the mortality estimate will be less than the unadjusted mortality estimate of 10.3%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904891     DOI: 10.1016/s0735-1097(10)80210-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Late sodium current in failing heart: friend or foe?

Authors:  Victor A Maltsev; Albertas Undrovinas
Journal:  Prog Biophys Mol Biol       Date:  2007-08-10       Impact factor: 3.667

Review 2.  [Current concepts in diagnosis and treatment of tachyarrhythmias].

Authors:  J O Schwab; B Lüderitz
Journal:  Internist (Berl)       Date:  2005-09       Impact factor: 0.743

Review 3.  Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart.

Authors:  Albertas Undrovinas; Victor A Maltsev
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

4.  The prognostic significance of frequency and morphology of premature ventricular complexes during ambulatory holter monitoring.

Authors:  Georges Ephrem; Michael Levine; Patricia Friedmann; Paul Schweitzer
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

5.  The systematic assessment of variations in medical practices and their outcomes.

Authors:  H Krakauer; R C Bailey; H Cooper; W K Yu; K J Skellan; G Kattakkuzhy
Journal:  Public Health Rep       Date:  1995 Jan-Feb       Impact factor: 2.792

6.  Development of more erratic heart rate patterns is associated with mortality post-myocardial infarction.

Authors:  Phyllis K Stein; QuyChi Le; Peter P Domitrovich
Journal:  J Electrocardiol       Date:  2008 Mar-Apr       Impact factor: 1.438

7.  Non-linear heart rate variability and risk stratification in cardiovascular disease.

Authors:  Phyllis K Stein; Anand Reddy
Journal:  Indian Pacing Electrophysiol J       Date:  2005-07-01

8.  First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.

Authors:  Pim Gal; Erica S Klaassen; Kirsten R Bergmann; Mahdi Saghari; Jacobus Burggraaf; Michiel J B Kemme; Christina Sylvest; Ulrik Sørensen; Bo H Bentzen; Morten Grunnet; Jonas G Diness; Nils Edvardsson
Journal:  Clin Transl Sci       Date:  2020-07-29       Impact factor: 4.438

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.